Averna Therapeutics News
3 articles
growth-positive
The former Moderna CMO, who led development of the company's Covid vaccine, tells "Globes" about Averna Therapeutics, which through gene editing is developing groundbreaking drugs.
Averna Therapeutics, formerly Exsilio Therapeutics, is a gene editing company based in Israel that recently raised $82 million in a Series A financing round. The company is led by Dr. Tal Zaks, former chief medical officer at Moderna, and is developing a novel approach to gene editing using mRNA technology to treat rare genetic diseases. The company aims to move to the preclinical trial stage with its technology, which has garnered interest due to its potential to treat a variety of diseases, including cancer and autoimmune disorders. CRISPR Therapeutics, a competitor, is one of the investors, indicating confidence in Avernas approach.
InvestmentProduct Stage
growth-positive
Tal Zaks's Israeli startup targets rare genetic diseases
Averna Therapeutics, formerly Exsilio Therapeutics, is a gene editing company based in Israel that recently raised $82 million in a Series A round. The company is led by Dr. Tal Zaks, former CMO of Moderna, and is developing a new approach to gene editing using mRNA technology. The company aims to treat rare genetic diseases and potentially develop drugs for cancer and autoimmune diseases. CRISPR Therapeutics, a competitor, is one of the investors, indicating confidence in Avernas potential. The company is in the preclinical trial stage and plans to keep research in Israel while sharing development with the US.
InvestmentManagement ChangesProduct Stage
growth-positive
Exsilio Therapeutics Launches with $82 Million Series A Financing to Develop Redosable Genomic Medicines for A Broad Range of Diseases
Exsilio Therapeutics, a biotechnology company developing genomic medicines, has emerged from stealth with $82 million in Series A financing. The funding round was co-led by Novartis Venture Fund and Delos Capital, with participation from several other investors. Exsilio focuses on creating genomic medicines that use mRNA and lipid nanoparticles to insert genes into safe harbor sites in the human genome. The company aims to treat genetic diseases, cancer, and autoimmune conditions with medicines that can be redosed and titrated. The investment will help Exsilio advance its genomic medicines and select promising lead candidates.
Investment
